Arch Oncology, a clinical-stage immuno-oncology, has closed a $105 million Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3x5 Partners, who were joined by new investors Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.

Arch Oncology's existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain, also participated in the round.